Highly potent SARS-CoV-2 neutralization by intravenous immunoglobulins manufactured from post-COVID-19 and COVID-19-vaccinated plasma donations
M Karbiener, MR Farcet, J Schwaiger… - The Journal of …, 2021 - academic.oup.com
M Karbiener, MR Farcet, J Schwaiger, N Powers, J Lenart, JM Stewart, H Tallman, TR Kreil
The Journal of Infectious Diseases, 2021•academic.oup.comFrom September 2020, some immunoglobulin lots from US plasma contained neutralizing
antibodies against the newly emerged severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2). Paralleled by the increasing numbers of post–coronavirus disease 2019
(COVID-19) donors, immunoglobulin lot antibody positivity increased to 93% by January
2021, at a mean titer of approximately 30 IU/mL. The correlation predicted that anti–SARS-
CoV-2 potency would reach 345 IU/mL by July 2021. In addition to post–COVID-19 donors …
antibodies against the newly emerged severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2). Paralleled by the increasing numbers of post–coronavirus disease 2019
(COVID-19) donors, immunoglobulin lot antibody positivity increased to 93% by January
2021, at a mean titer of approximately 30 IU/mL. The correlation predicted that anti–SARS-
CoV-2 potency would reach 345 IU/mL by July 2021. In addition to post–COVID-19 donors …
Abstract
From September 2020, some immunoglobulin lots from US plasma contained neutralizing antibodies against the newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Paralleled by the increasing numbers of post–coronavirus disease 2019 (COVID-19) donors, immunoglobulin lot antibody positivity increased to 93% by January 2021, at a mean titer of approximately 30 IU/mL. The correlation predicted that anti–SARS-CoV-2 potency would reach 345 IU/mL by July 2021. In addition to post–COVID-19 donors, the rapidly increasing number of plasma donors vaccinated against COVID-19 resulted in a mean antibody titer of >600 IU/mL in July 2021 immunoglobulin lots, with SARS-CoV-2 antibody titers for several lots even higher than those of earlier produced hyperimmune globulin products.
Oxford University Press